Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0023890 (cirrhosis)
 42,195 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The present study demonstrates that the fibrinolytic activity is significantly increased and the level of plasminogen antiactivator diminished in the blood of patients with advanced liver cirrhosis and chronic aggressive hepatitis as compared with the values for healthy subjects. Total fibrinogen concentration was similar in patients and controls. However, electrophoresis of plasma with the use of SDS-polyacrylamide gel (3.5%) showed considerable differences in the composition of fibrinogen fractions. Lower molecular weight (LMW and LMW1) clottable protein was significantly (p less than 0.01) increased in the patients. In two out of 22 patients the higher molecular weight (HMW) fraction was virtually absent. In vitro incubation (37 degrees C for 48 hr) of diluted (1:10) plasma from a patient resulted in extensive degradation of a low-solubility fibrinogen fraction (HMW) previously added to the sample. No degradation was observed in any undiluted plasma samples. It is concluded that the increased concentration of lower-molecular-weight forms of clottable protein in the blood of patients with liver disease is probably related to increased in vivo degradation rather than abnormal synthesis. An association rather than a direct correlation with fibrinolytic activity was found.
 ...
PMID:Abnormal fibrinogen heterogeneity and fibrinolytic activity in advanced liver disease. 40 38

A new low molecular weight protein was purified from the urine of uraemic patients. The protein was found to be glycoprotein with a molecular weight of 31 500, determined by SDS-polyacrylamide gel electrophoresis, and a carbohydrate content of 19%. It was electrophoretically heterogenous and migrated in the slow alpha1-region. The mean serum level in 20 apparently healthy individuals was 32+/-10 mg/1. The serum level was normal in 5 patients with severe reduction of plasma protein synthesis caused by cirrhosis of the liver but elevated in patients with a decreased glomerular filtration rate. The mean urinary excretion in 5 healthy individuals was 1.3 mg/24 h. Increased excretion was seen in 10 patients with varying degrees of uraemia.
 ...
PMID:alpha1-Microglobulin, a new low molecular weight plasma protein. 100 Aug 59

The serum and erythrocyte membrane proteins of patients with cirrhosis were studied. Recent work on abnormalities of the erythrocyte membrane resulted in the identification of several types of membrane skeleton lesions. The different techniques for separation of membrane proteins have been revised and compared. These were studied on slabs using the SDS-polyacrylamide gel and discontinuous buffer system with a linear concentration gradient of 5-15% (w/v). Serum proteins were separated by using continuous buffer system with a linear concentration gradient of 4-30%. A decreased in serum and red cell membrane proteins in those patients, were observed.
 ...
PMID:[Changes in erythrocyte membrane proteins in patients with cirrhosis]. 179 53

In vitro proteolysis of red cell membranes has been studied by means of electrophoretic separation on SDS-polyacrylamide gel of solubilized ghost proteins and subsequent densitometry of separated, stained bands; the amounts of major membrane proteins were measured in ghosts either with inhibited or with allowed proteolysis in the following cases: 15 patients suffering from hereditary spherocytosis (HS) with variable degree of spleen enlargement, eight cirrhotic patients with spleen enlargement and 12 healthy blood donors as control group. Proteolysis was present to a greater extent in HS patients with larger splenomegaly, lesser in HS with smaller splenomegaly, and was comparable to healthy controls both in splenectomized HS and in patients with spleen enlargement due to liver cirrhosis. The results suggest the involvement of splenomegaly in the enhancement of in vitro proteolysis in HS red cell membrane; it is probably attributable to joint effects of the damage induced in red cells by prolonged retention within haemolysing spleen together with the abnormalities genetically affecting the structure of HS red cell membrane.
 ...
PMID:Role of spleen in hereditary spherocytosis: evidence for increased in vitro proteolysis of red cell membrane. 164 33

Ascitic fluid from tumour patients (hepatoma, gastric cancer, gallbladder cancer, colorectal cancer, ovarian cancer) and from non-malignant diseases (liver cirrhosis, congestive heart failure) were compared with respect to their content of determinants of the fibrinolytic system, tissue-type plasminogen activator antigen (t-PAag) and activity (t-PAact), urokinase-type plasminogen activator antigen (u-PA) and plasminogen activator inhibitor activity (PAI). Furthermore, SDS-polyacrylamide slab-gel electrophoresis (SDS-PAGE) was performed to evaluate molecular weight distribution of the detectable fibrinolytic parameters. In malignant ascites, PAI activity was three to four times higher, and increased complex formation of PAI with t-PA could be demonstrated, compared with non-malignant ascitic fluid. Tissue-type plasminogen activator antigen and activity showed a similar concentration in ascites of both study groups. Urokinase-type plasminogen activator antigen was detectable neither in ascites of malignant nor in ascites of non-malignant origin. It is concluded that t-PA is the physiological plasminogen activator in ascites and that increased PAI levels followed by increased complex formation between t-PA and PAI might reflect a reaction of the peritoneum.
 ...
PMID:Plasminogen activators and plasminogen activator inhibitor in malignant and non-malignant ascitic fluid. 285 12

A protein of 154 amino acids, predicted to be encoded by the X-open reading frame of the hepatitis B virus (HBV) genome, was synthesized in an in vitro translation system from SP6 transcripts containing the X-coding sequence. As characterized by SDS-PAGE and immunoprecipitation this X-protein possesses the expected molecular weight of 17 kDa and reacts specifically with rabbit antisera directed against a fusion protein from Escherichia coli that contained 145 of the 154 amino acids from the X-sequence. The X-protein, radiolabeled with [35S]methionine, provided a sensitive and specific antigen to screen for anti-X antibodies in sera from HBV patients. Positive signals were obtained preferentially in subjects suffering from HBV-induced liver cirrhosis or primary hepatocellular carcinoma (PHC), i.e., individuals that had been exposed for an extended time period to HBV gene products. Carefully controlled experiments failed to reveal the presence of X-related proteins specific to liver specimens from HBV patients.
 ...
PMID:Synthesis of the X-protein of hepatitis B virus in vitro and detection of anti-X antibodies in human sera. 303 93

The level of serum orosomucoid, the amount of sialic acid binding to it, and the binding rate of sialic acid to orosomucoid in normal individuals and in patients with chronic hepatitis and liver cirrhosis were determined by affinity column chromatography, SDS electrophoresis and the method of Warren. Although no apparent changes in the level of serum orosomucoid or the amount of sialic acid binding to it in each group were seen, the binding rate of sialic acid to orosomucoid in chronic persistent hepatitis and chronic active hepatitis showed a remarkable increase, compared with normal individuals and patients with liver cirrhosis. Furthermore, the binding rate of sialic acid in liver cirrhosis was the lowest in each group.
 ...
PMID:The binding rate of sialic acid to serum alpha 1-acid glycoprotein in patients with chronic hepatic injury. 331 65

Hepatic expression of sialylated difucosyl Lex antigen (SDLex, NeuAc alpha 2-3Gal beta 1-4(Fuc alpha 1-3)GlcNAc beta 1-3Gal beta 1-4(Fuc alpha 1-3)GlcNAc beta 1-) was studied with monoclonal antibody FH6, which defines this structure. Hepatocytes in the severe form of chronic active hepatitis and liver cirrhosis strongly expressed SDLex. The antigen was only weakly and focally detected in chronic persistent hepatitis. The mild form of chronic active hepatitis showed intermediate expression. SDLex expressed along the liver cell membranes displayed a honeycomb pattern when extensively expressed in the severe form of chronic active hepatitis or in liver cirrhosis. Cytoplasmic expression was faint and focal. Preferential tissue distribution was at the periphery of the hepatic lobules where the distruction of the limiting plate was present. The antigen was also expressed in sinusoidal lining cells and polymorphonuclear cells but not in the biliary epithelia. Hepatocytes expressing SDLex did not express related carbohydrate antigens, ie, Type 2 chain N-acetyllactosamine, Lex, and sialylated Lea. On subcellular fractionation, the microsome fraction contained the majority of the antigen activity. SDS-PAGE and Western blot analysis revealed one major SDLex-active glycoprotein with an apparent molecular weight of 110 kilodaltons. This glycoprotein was different from SDLex-active glycoproteins found in the sera of cancer patients. No ganglioside showed FH6 reactivity. These results indicate that liver cells in active inflammatory lesion expressed a novel glycoprotein carrying SDLex antigen in honeycomblike membrane-associated pattern.
 ...
PMID:Hepatocellular expression of a novel glycoprotein with sialylated difucosyl Lex activity in the active inflammatory lesions of chronic liver disease. 334 53

Increased serum fibrinogen degradation product (FDP) in liver cirrhosis and hepatic carcinoma as measured by latex agglutination was analyzed by means of SDS-polyacrylamide gel electrophoresis followed by immunoblotting with anti-fibrinogen antibody. The antibody used in this study reacts with fibrinogen, fragment X, Y, D-D, D and E. The validity of this technique was confirmed by the analysis of the serum samples from patients with definite diagnosis of disseminated intravascular coagulation. Serum samples of 14 patients out of 18 with elevated FDP values and severe liver diseases were shown to contain no plasmic digest of fibrin or fibrinogen. By using the SDS-gel electrophoresis after disulfide bond reduction, seven serum samples from these 14 patients, who were shown to have no plasmic digest in serum, were found to contain unclottable fibrinogen retained in sera, while the remaining seven samples were revealed to have fibrin monomer in their sera. Four serum samples from the 18 patients were shown to have plasmic digest of fibrinogen, but these patients had additional diseases leading to intravascular coagulation.
 ...
PMID:Analysis of fibrinogen degradation product in severe liver disorders by immunoblotting. 343 74

The in vivo formation of the sulfate ester of glycolithocholate is a critical step in the elimination of this hepatotoxic bile salt. Rhesus monkeys fed chenodeoxycholate or ursodeoxycholate, the precursors of lithocholate, develop frank cirrhosis in association with accumulation of nonsulfated glycolithocholate in bile. An enzyme catalyzing the formation of glycolithocholate-3-sulfate has been isolated from hepatic cytosol of adult female rhesus monkeys and has been purified 146-fold. When reduced it appears as a 30 kD band on an SDS-polyacrylamide gradient gel. It has a pH optimum of 7.0 and is stimulated by low concentrations of Mg2+ (up to 2 mM), but does not have an absolute requirement for this metal ion. The kinetics of this enzyme have been investigated to ascertain whether its reaction mechanism can account for the poor in vivo rate of glycolithocholate sulfation. Inhibitor studies with an oxidized metabolite of lithocholate, 3-keto-5 beta-cholanoate, showed that the latter is a competitive inhibitor of glycolithocholate and is noncompetitive with the active form of sulfate, 3'phosphoadenosine-5'-phosphosulfate. The monophosphonucleotide 3'-AMP is a competitive inhibitor of 3'phosphoadenosine-5'-phosphosulfate, and is noncompetitive with glycolithocholate. These observations are consistent with a sequentially ordered Bi Bi reaction mechanism in which the bile salt is the first substrate to bind to the enzyme. Such a reaction mechanism for bile salt:3'phosphoadenosine-5'-phosphosulfate:sulfotransferase would be, therefore, the first time in which the sulfate acceptor (the bile salt) is the initial substrate to bind to a sulfotransferase. These studies have shown that although rhesus monkeys have a liver enzyme capable of forming the sulfate ester of glycolithocholate, its reaction mechanism and the potent inhibition caused by simple metabolites, such as 3-keto-5 beta-cholanoate, may serve to under-express the activity of the enzyme in vivo.
 ...
PMID:Evidence for an ordered reaction mechanism for bile salt: 3'phosphoadenosine-5'-phosphosulfate: sulfotransferase from rhesus monkey liver that catalyzes the sulfation of the hepatotoxin glycolithocholate. 347 Apr 20


1 2 3 Next >>